The FDA is slated to announce its decision on Regeneron Pharmaceuticals Inc.’s (REGN) supplemental Biologics License Application for a 12-week dosing interval of EYLEA Injection in patients with wet age-related macular degeneration on August 11, 2018.For wet AMD, the current recommended dose for EYLEA is 2 mg administered by injection in the eye every two months (eight weeks) following three initial monthly (every four weeks) injections. EYLEA may also be dosed once per month.The global annual net sales of Eylea in 2017 were $5.93 billion, up 14% over 2016.REGN closed Wednesday’s (Jul 25) trading at $374.49, up 0.46%.